{
    "clinical_study": {
        "@rank": "102358", 
        "arm_group": [
            {
                "arm_group_label": "Treatment period 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment period 2", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of this trial is to investigate the\n      pharmacokinetics and pharmacodynamics of insulin X14 30/70 PreMix compared to human insulin\n      30/70 PreMix in healthy volunteers."
        }, 
        "brief_title": "Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 in Healthy Volunteers", 
        "completion_date": {
            "#text": "December 1995", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Healthy"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Non-smokers\n\n          -  BMI (body mass index) maximum 27 kg/m^2\n\n          -  HbA1c (glycosylated haemoglobin A1c): 3.4-6.1%\n\n          -  FBG (fasting blood glucose) maximum 6.0 mmol/L"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01707160", 
            "org_study_id": "ANA/DCD/031"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Treatment period 1", 
                    "Treatment period 2"
                ], 
                "description": "One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order", 
                "intervention_name": "biphasic insulin aspart 30", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment period 1", 
                    "Treatment period 2"
                ], 
                "description": "One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order", 
                "intervention_name": "biphasic human insulin 30", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin", 
                "Insulin, NPH"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 15, 2012", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Leeds", 
                    "country": "United Kingdom", 
                    "zip": "LS2 9NG"
                }
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Double-blind 2 Way Crossover Trial to Investigate the Pharmacokinetics and Pharmacodynamics of Insulin X14 30/70 PreMix Compared to Human Insulin 30/70 PreMix in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Lisbeth V. Jakobsen, M.sc.", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 1995", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Area under the Curve", 
            "safety_issue": "No"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01707160"
        }, 
        "responsible_party": {
            "name_title": "Public Access to Clinical Trials", 
            "organization": "Novo Nordisk A/S"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum insulin concentration (Cmax)", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Time to maximum insulin concentration (tmax)", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Minimum glucose concentration (Cmin(glu))", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Time to minimum glucose concentration (tmin(glu))", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Adverse events", 
                "safety_issue": "No"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 1995", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}